Search alternatives:
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant main » significant gap (Expand Search), significant amount (Expand Search), significant cause (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
significantly reported » significantly related (Expand Search), significantly restored (Expand Search), significantly predicted (Expand Search)
significant main » significant gap (Expand Search), significant amount (Expand Search), significant cause (Expand Search)
main decrease » gain decreased (Expand Search), mean decrease (Expand Search), small decrease (Expand Search)
reported case » reported cases (Expand Search), reported use (Expand Search), imported cases (Expand Search)
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Henoch-Schönlein purpura nephritis associated with monoclonal gammopathy of renal significance: a case report
Published 2019“…The Henoch-Schönlein purpura nephritis (HSPN) that cannot be relieved by treatment with glucocorticoid and immunosuppressive agents suggests the presence of monoclonal gammopathy in adult patients. The present study reports on a single case of HSPN associated with IgA-κMGRS. …”
-
9
-
10
Data Sheet 1_Case report: Achieving significant tumor reduction in advanced pancreatic adenocarcinoma.docx
Published 2024“…However, certain genetic profiles, such as BRCA1/2 mutations, high tumor mutational burden (TMB), or microsatellite instability-high (MSI-H), may enhance sensitivity to these therapies. This report presents two cases of advanced pancreatic cancer with BRCA1/2 mutations treated with a combination of chemotherapy and immune checkpoint inhibitors. …”
-
11
-
12
Multivariate logistic regression of significant variables stratified by age.
Published 2025Subjects: -
13
-
14
-
15
-
16
-
17
Data Sheet 1_Case Report: Efgartigimod demonstrates significant clinical efficacy in double seropositive myasthenia gravis: a case report of a rare variant and analysis of pathomechanisms.pdf
Published 2025“…Currently, no standardized therapeutic protocol exists for DSP-MG due to its scarcity and clinical heterogeneity. Herein, we report a case of a 68-year-old female patient with DSP-MG who showed significant clinical improvement during an acute exacerbation after treatment with the FcRn antagonist efgartigimod, following the failure of conventional therapy. …”
-
18
-
19
-
20